Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management
Stockholm, Sweden – August 16 – Biosergen AB ("Biosergen" or the “Company"), a clinical stage biotech company specializing in the development of innovative anti-fungal therapies, is pleased to announce significant guarantees from its largest shareholders and executive management to fully exercise their warrants during the ongoing warrant exercise period.Östersjöstiftelsen and Rosetta Capital, the Company’s largest shareholders, will exercise all their warrants. In addition CEO Peder M. Andersen and CFO Niels Laursen will subscribe to all of their warrants. Moreover, COO Tine Olesen, who